Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
A Liberal Democratic Party (LDP) study group on pharmaceutical policies on November 20 submitted a proposal towards the FY2024 reimbursement and tax policy reform to the health minister, calling for better rewarding innovation being quickly brought to Japan by bolstering…
To read the full story
Related Article
- LDP Pharma Study Group Calls for Expanding Sakigake Premium, Creating New Premium
November 15, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…